Molecular Pharmacology Ltd (MLPH)

[HokieHead]

Freaking monster. No sellers. may bust .10 today at this rate...

[ulfahl]

$MLPH talk still under way! :)

Could there be more in store for MLPH? I saw a lot of traders out there in the chats and boards talking about MLPH today. After a move like today, MLPH has MONSTER BUZZ. Obviously it's safest to book profits quickly and walk away (amateur biased opinion), but EVERYBODY out there just put MLPH on their radar. It's definitely worth keeping an eye on for more hot action...just in case further profits are available. It pulled back at the end of the day and closed up 325% at only .034. It hit .09 today, so if it did it again tomorrow that's another 165% gain from today's close.

[ulfahl]

$MLPH more news coverage:

Six Penny Stocks with Heavy Volume to Watch for Wednesday

6/5/2012 8:55:59 PM

Molecular Pharmacology Limited (PINK:MLPH) traded as high as $.09 during Tuesday’s trading session and last traded at $.034 for a gain of 325% from the Monday’s close… MLPH shares have traded as high as $.027 over the past 52 weeks, which is 25.93% off that high at last traded stock price.


Read more: http://fyxnews.com/smw/28482/Six-Penny-Stocks-with-Heavy-Volume-to-Watch-for-Wednesday-#ixzz1x1EVplUu

Molecular Pharmacology (USA) Ltd. (OTCBB: MLPH) Hitting Staggering Levels Despite Obvious Obstacles to Business Strategy
Posted on June 05, 2012 by OTC Equity

Despite no news being released and no evidence of an impending development shares of Molecular Pharmacology (USA) Ltd. (OTCBB: MLPH) have skyrocketed on Tuesday, surging nearly 500% to hit a high of 0.0900 just days after sinking to a low of 0.0080. Those shares have since slipped back around the 0.0499 level but even that share price is hard to justify as too is the trading volume which has already surpassed the 2.5 million mark, astronomically higher than their 50-day average of less than 34,000 and 200-day average of less than 22,000. Obviously a promotional campaign has set MLPH shares off and at this point trying to determine if there's anything left to gain by getting in now can be difficult. One thing is for sure, investors aren't going to be getting much information from MLPH as they have no press releases to speak of; instead investors are forced to read through th...

http://www.otcequity.com/exclusive.php?post=2232

[ulfahl]

$MLPH News coverage - looking for more movement!

Molecular Pharmacology Ltd. (MLPH) Stock Gains Big in Yesterday’s Session
Wednesday, June 6th, 2012 | Filed under Breaking News,Internet | Posted by Ken Bosket
Shares of Molecular Pharmacology Ltd. (PINK: MLPH), a development-stage company engaged in the development and commercialization of analgesic and anti-inflammatory molecule called Tripeptofen, saw a huge rally in Tuesday’s trading session.
The penny stock of MLPH ended the day 325% higher at $0.0340, with volume up from daily average of 3,789 to 3.36 million.
Molecular Pharmacology made a 10Q filing back in April this year. The filing showed that MLPH has not generated any revenue since its inception.
According to the filing, the company had $13,435 in cash and cash equivalents at the end of March 31, 2012.

http://www.tech24.org/114471molecular-pharmacology-ltd-mlph-stock-gains-big-in-yesterday%E2%80%99s-session.html

[Capkewl]

No Kidding LOL

[$$$TOCK 007]

MLPH- NICE SS- OS 43.50M , AS 200M

more low float penny, try here.Thanks

http://investorshub.advfn.com/Penny-$$-Tiny-Float-*-Low(OS-&-AS)-24974/

[MrsPennyStocks]

MLPH was the winner today at Penny Stock Rumble
end of day email came in. early investors did will on this.

[ulfahl]

$MLPH MMs painting red on my buys at ,034! lol
$MLPH will move tomorrow, good volume for today. 10Q due soon.

[ulfahl]

$MLPH looking good here for the next move. Up 523% - this will move even further! $MLPH will move all week when more get wind of it!

MLPH – Molecular Pharmacology

Molecular Pharmacology (USA) Limited is a public biotechnology company dedicated to the discovery and development of analgesic and anti-inflammatory products based on the proprietary MPL-TL compound. MPL USA holds the exclusive worldwide rights to develop new and fast-acting analgesic and anti-inflammatory products based on MPL-TL . MPL has entered into an exclusive US distribution and supply agreement with Molecular Pharmacology Limited (MPL Australia), the developer of MPL-TL. Through this agreement MPL holds exclusive US sales, marketing and distribution rights for MPL-TL, and the mandates of both companies will be pursued under the corporate umbrella of MPL. As such, all references to or discussion of events or actions historical, current, or planned by either Molecular Pharmacology (USA) Limited or Molecular Pharmacology Limited-Australia will be referred to as activity or events undertaken by MPL.

We’ve been hurtin’ lately, and this is an alert that LITERALLY is here to cure the pain. This is the day-trading alert of a lifetime. A thinly traded low float beauty to say the least.

MLPH holds the exclusive worldwide rights to develop, market, and sell a brand NEW and fast-acting analgesic and anti-inflammatory product.

The products are based on their proprietary compound called MPL-TL (aka Tripeptofen). Tripeptofen is a new key active ingredient that targets a different part of the pain and inflammation cascade than other analgesic/anti-inflammatory drugs. It is the first significant new topical analgesic discovery in nearly 50 years and will drive new products and opportunity in the $36.5 billion analgesia and anti-inflammatory industry.

Delivered through the skin, analgesic products based on MPL-TL are expected to be fast acting with localized effects and minimal anticipated drug interactions or side effects.

MLPH holds the exclusive worldwide rights to develop new and fast-acting analgesic and anti-inflammatory products based on MPL-TL. The parent product for MPL-TL has been used and tested for nearly two decades and has been shown to be fast acting, safe and effective.

MPL-TL is the name MLPH has given to an amino-acid hydrolysate complex that exhibits strong anti-inflammatory and analgesic properties in human populations. Solid data on MPL-TL points to a very important new anti-inflammatory and analgesic agent, with a much more rapid onset of action than current products on the market.

With the discovery of a completely NEW active ingredient, MLPH is largely free of competitors and restrictive patents.

Product development opportunities range from “traditional remedy” products like pills, to topical anti-inflammatory products.

MLPH has some big MAJOR name research partners!

Curtin University of Technology is Western Australia’s largest university. They are a world-class, internationally focused institution (www.curtin.edu.au) and a research partner of MLPH.

The Western Australian Biomedical Research Institute (WABRI) brings together the expertise of more than 70 scientists, many with well-established international reputations in the fields of biomedical sciences & pharmacology. Another top notch partner.
(www.wabri.org.au)
Fisher Biotec is an innovative 100% Australian company founded in 1996 by a group of key molecular biologists. The staff of Fisher Biotec have international experience in both research and commercial development of products designed to solve research problems and help to diagnose health disorders.

(www.fisherbiotec.com)

ORION is committed to the manufacture of a range of quality products, which are essential to everyday healthcare.
(www.orion.net.au)


The MPL-TL primary product has been extensively tested and, to-date, has not been related to any significant side effects. It has a specific advantage because it is topical, and provides fast relief at the site of pain and inflammation. In addition, MPL-TL appears to target a different part of the pain and inflammation cascade than existing products, which could mean it could not only replace current pain treatments, but could also work with them to potentially enhance pain treatment further.
The market is ready for new, safer and more effective pain-relief products with fewer side effects. Molecular Pharmacology Ltd. (MPL) believes that with MPL-TL (Tripeptofen), they will be able to establish and secure a solid position within the pain-relief market that will both attract a portion of the old market and create new customers who will not or cannot use current products.

Seems amazing, but of course…

** Remember that every single alert I send is very volatile and risky. Any one of them could turn into a big loser. In my personal opinion, no matter how much potential any company has, 99% of the time all that matters is HOW THE STOCK TRADES. If a stock doesn’t trade well, nothing else matters. Don’t believe the hype. Be sure to use a tight stop, book profits quickly on these volatile trades, never let any one trade move too far against you, watch out for gaps, make sure the stock is trading in a healthy way before you enter, and monitor it closely to make sure momentum is positive. It’s thinly traded with a low float, so watch out for extreme volatility (Amateur biased unlicensed opinions) **

Now we’re getting to the amazing part…

MPL-TL will be developed primarily as a generic ingredient – a key active ingredient – much like aspirin or ibuprofen. In this form, it will be sold to external formulators for incorporation into thousands of new analgesic products for which there is a ready path to market and a willing market place.

MPL may elect to retain specific products or applications and commercialize those directly, although the Board of Directors will make that decision at an appropriate time. The company will also be actively exploring MPL-TL as a potential oral or even injectable analgesic, although the major focus for the first 3 to 5 years will be to establish a clear market lead in the area of topical analgesics.

So what does that mean in plain English??

Think about Tylenol as an example. Tylenol is the most well known brand name for a generic key ingredient called Acetaminophen. Acetaminophen is the active ingredient in THOUSANDS of products. Tylenol is pure Acetaminophen, but countless other medicines like NyQuil, Robitussin, and virtually EVERY over-the-counter medicine brand uses Acetaminophen in at least one of their products. Many prescriptions like Vicodin also use Acetaminophen as a key ingredient. The market is enormous.

Think of it like this…MLPH doesn’t own the patent to “Tylenol,” MLPH owns the patent for Acetaminophen!!!! (Not literally Acetaminophen, I’m just using Tylenol/Acetaminophen as an example) So MLPH owns the exclusive worldwide rights for the active ingredient! That means they can develop their own brand of product, but more importantly, MLPH can license Tripeptofen out so countless other companies and top brands can make their own Tripeptofen products!!!

This is an unbelievable opportunity, and what’s more unbelievable is that this company is trading below a penny!

I see the ask price as I write this is almost 2 cents, but even at MUCH higher prices than that, MLPH holds unbelievable potential for such a low priced stock. If this stock were to be “discovered” by Wall Street or even other penny traders, I think a far higher valuation could be justified based on the incredibly rare potential that I believe MLPH possesses.

Watch this one like a hawk, I wouldn’t be surprised to see OUTRAGEOUS GAINS if all goes well on MLPH today. Look out for RED HOT day-trading action.
PSA – Stock Psycho

[$$$TOCK 007]

I never load if the stockboard followers over 300 board marked, always hunting for penny with the sotckboad with low Followers(low board marke)

MLPH is the one I like to. no matter who run it.

[SUPERFREAK]

It's a pump guys

[dafuji]

HUGE MERGER Happening so it seems.

[stockinvest]

what target price are we talking here?

[$$$TOCK 007]

MLPH-650%- low OS

[Penny Machine]

Big PPS Gaps coming up Quick!!!

[bewenched]

New 10-k

[Checkie]

Good question!

[Bonga]

Where is everyone?

[BerryBuck]

rock on nlightn!

[nlightn]

hey there berrybck,...i have had MLPH on my 'to do list' for a while and have just gotten around to take a look.

so at this point i don't really know any more than you and possibly less.

so,..."take a look" for me means i will be doing some DD on the company and its fundamentals and technicals,...

what ever i discern/discover i will pass on and see if we can create an intelligent and informed investment decision,...

or not. :)

GLTY

[mrcopfer]

Ive been in this stock since .35 cents. I got in when I recieved a fax pump on MLPH, and its done nothing but tumble down here to bottom. What gives with this company ??? An further info is greatly appreciated.

[BerryBuck]

does this company have any income at this point? looks to still be developmental. price is down near 52 week low which i like. assuming that is there is a substantial chance they wre about to bounce off of it.
talk to me nlightn..

berry

[nlightn]

Replicated Studies Open New Product Opportunities in the Rheumatoid Arthritis Market

July 28, 2006

Molecular Pharmacology (USA) Limited (OTCBB: MLPH) announced today that independent, replicated and multi-centered in-vitro studies had shown that the company's anti-cytokine drug, MPL-104, potently inhibits the secretion of TNF-alpha in inflammatory conditions. The secretion of the cytokine TNF-alpha underlies a range of debilitating inflammatory diseases such as rheumatoid arthritis, lupus, Crohn's disease, psoriasis, and ankylosing spondylitis, and is considered to be the main factor in driving inflammation.

TNF-alpha inhibitors for the treatment of Rheumatoid Arthritis (RA) are not new, as oral products such as Enbrel, Centocor/Schering-Plough/Tanabe's Remicade (infliximab), and Humira already exist in the market place. According to Decision Resources, Inc. (http://www.decisionresources.com/), the existing products had combined sales of $4.6 billion in 2005, and they project this market segment will undergo robust growth in the United States, United Kingdom, France, Germany, Italy, Spain, and Japan reaching more than $10 billion by 2015.

"What makes MPL-104 such an exciting project is that it is directed at producing products that do not directly compete with the current market leaders, and complement their functionality," said MPL President and Chief Executive Officer Jeffrey Edwards. "Irrespective of how well medicated RA sufferers are, it is very common for them to have one or more unresponsive joints. Elevating systemic medication levels to accommodate these is not a clinical option, because of the potential of adverse side effects. This is the therapeutic area where we believe MPL-104 will provide real benefits."

MPL-104 appears to be one of the very rare TNF-alpha inhibitory drugs that is small enough to be administered topically. This allows it to be formulated as a cream or serum and applied directly to the effected area or joint, without altering systemic levels by any significant amount. We believe this will allow MPL-104 to be used to support and augment the total clinical efficacy of existing market leading drugs rather than be competitive to them.

In addition to the RA market opportunity, we expect the benefit of isolated application and local action has the potential to deliver similar benefits in the treatment of other inflammatory conditions, a market projected to increase to $47.8 billion by 2010. (BCC Research -- www.bccresearch.com/biotech/B219.html)

MPL-104 emerged following an extensive research and isolation program designed to reveal the biological mechanism behind an analgesic and anti-inflammatory product that had been approved and marketed successfully in Australia for almost 18 years with an unblemished safety and efficacy record in humans.

"We believe this provides MPL with a very early path to market, and a stepping-stone platform into the European, Asian and ultimately the US markets for a range of disease specific products that utilise the Company's broadening biological mediator platform."

About Molecular Pharmacology (USA) Limited

Molecular Pharmacology (USA) Limited (OTCBB: MLPH) is a public biotechnology company dedicated to the discovery and development of analgesic, anti-inflammatory and anti-cytokine products based on the proprietary MPL-TL compound.

MPL-USA, through its Australian subsidiary, holds the exclusive worldwide rights to commercialize and develop products and product derivates, based on the MPL-TL biological mediator platform.

MPL-TL is currently approved for sale and use in Australia, under the brand name of ThermaLife, for the temporary relief of muscular and arthritic pain. A second product, TL-B, is in late stage regulatory submission with the Australian regulatory body.

MPL-USA has established research and development activities in the USA, Australia, South East Asia and Europe to explore additional product opportunities in the management of locally acting biological mediators involved in the secondary injury cascade.

For more information on MPL-USA, please visit www.mpl-usa.com.


Source: Market Wire (July 28, 2006 - 8:55 AM EDT)

News by QuoteMedia
www.quotemedia.com

[nlightn]

Molecular Pharmacology Concludes Acquisition Of Pharmaceutical Development Company
May 9, 2006

Molecular Pharmacology (USA) Limited (OTC BB: MLPH) is pleased to announce that it has acquired 100% of the issued and outstanding share capital of Molecular Pharmacology Limited ("MPLA"), an Australian corporation. The transaction was originally announced by the Corporation in a press release dated November 29, 2005 and was subsequently approved by a majority of the stockholders of the Company at a stockholders meeting held on April 21, 2005. As a result of the transaction, PharmaNet Group Limited ("PharmaNet"), the former parent company of MPLA, now controls approximately 66.89% of the Corporation's issued and outstanding share capital. The transaction between the parties closed in escrow with an effective closing date of May 8, 2006.

The acquisition of MPLA provides the Corporation an immediate and solid international foundation and will allow it to grow its business into all major geographical markets. The assets and resources of the Australian company and its existing teams and development programs will augment the Corporation's plan to develop safe and effective pain and inflammation management products.

MPLA has established key personnel, a medical team and development and testing capabilities in Australia and Singapore through leading universities, government testing facilities and private research centers. The Corporation will continue to maintain these assets and has moved to secure key employees and relationships going forward.

For further detail about the transaction, MPLA and the business of the Corporation going forward please refer to the Notice of Meeting and Management Information Circular of the Corporation dated March 31, 2006, available on www.sec.gov.

About Molecular Pharmacology (USA) Limited

Molecular Pharmacology (USA) Limited (OTC BB: MLPH) is a public biotechnology company dedicated to the discovery and development of analgesic and anti-inflammatory products based on the proprietary MPL-TL compound. MPL USA holds the exclusive worldwide rights to develop new and fast-acting analgesic and anti-inflammatory products based on MPL-TL. For more information on MPL USA, please visit www.mpl-usa.com.


Source: Market Wire (May 9, 2006 - 9:00 AM EDT)

News by QuoteMedia
www.quotemedia.com

[nlightn]

Molecular Pharmacology to Acquire Topical Cox-2 Inhibitor Candidate as Part of Australian Transaction
May 3, 2006 - 9:36 AM EDT

LOS ANGELES, May 3, 2006 (PRIMEZONE) -- Molecular Pharmacology (USA) Limited (OTCBB:MLPH) announced today the discovery of a new topically applied COX-2 inhibitor drug candidate MPL-356, following results by MDS Pharma Services (MDS), one of the world's leading independent pharmacology testing laboratories. The results were from a development program commenced by Molecular Pharmacology Limited Australia (MPLA), which is in the process of being acquired by MPL-USA and returned encouraging results in COX-2 inhibition studies. The study and follow-up replication and dose response study, conducted by MDS's Taiwan laboratory, evaluated MPL-356 in the inhibition of human Cyclooxygenase COX-2 in vitro with results reporting inhibition of up to 90% of the key pro-inflammatory enzyme.

The COX-2 enzyme is the primary biological target in the treatment of osteo-arthritis, however, safety concerns regarding potential side effects of some oral COX-2 inhibitors have resulted in global product withdrawals. Topical COX-2 inhibitors have the potential to avoid such systemic side effects while retaining the anti-arthritic benefits.

CS-356 was discovered by Cambridge Scientific Pty Ltd., and, under the terms and conditions of the exclusive world-wide license between Cambridge and MPLA, MPL-USA is automatically granted the world-wide exclusive rights to commercialize the topical analgesic and anti-inflammatory properties of MPL-356 in humans.

About Molecular Pharmacology (USA) Limited

Molecular Pharmacology (USA) Limited (OTCBB:MPLH) is a public biotechnology company dedicated to the discovery and development of analgesic and anti-inflammatory products based on the proprietary MPL-TL compound. MPL USA holds the exclusive worldwide rights to develop new and fast-acting analgesic and anti-inflammatory products based on MPL-TL. For more information on MPL USA, please visit www.mpl-usa.com.


CONTACT: Molecular Pharmacology (USA) Limited
Ian Downs
[phone]


Source: PrimeZone (May 3, 2006 - 9:36 AM EDT)

News by QuoteMedia
www.quotemedia.com